Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins

Background Immune checkpoint inhibition holds promise as a novel treatment for pancreatic ductal adenocarcinoma (PDAC). The clinical significance of soluble immune checkpoint (ICK) related proteins have not yet fully explored in PDAC. Methods We comprehensively profiled 14 soluble ICK-related proteins in plasma in 70 PDAC patients and 70 matched healthy controls. Epidemiological data of all subjects were obtained through structured interviews, and patients’ clinical data were retrieved from electronical health records. We evaluated the associations between the biomarkers with the risk of PDAC using unconditional multivariate logistic regression. Consensus clustering (k-means algorithm) with significant biomarkers was performed to identify immune subtypes in PDAC patients. Prediction models for overall survival (OS) in PDAC patients were developed using multivariate Cox proportional hazards regression. Harrell’s concordance index (C-index), time-dependent receiver operating characteristic (ROC) curve and calibration curve were utilized to evaluate performance of prediction models. Gene expressions of the identified ICK-related proteins in tumors from TCGA were analyzed to provide insight into underlying mechanisms. Results Soluble BTLA, CD28, CD137, GITR and LAG-3 were significantly upregulated in PDAC patients (all q < 0.05), and elevation of each of them was correlated with PDAC increased risk (all p < 0.05). PDAC patients were classified into soluble immune-high and soluble immune-low subtypes, using these 5 biomarkers. Patients in soluble immune-high subtype had significantly poorer OS than those in soluble immune-low subtype (log-rank p = 9.7E-03). The model with clinical variables and soluble immune subtypes had excellent predictive power (C-index = 0.809) for the OS of PDAC patients. Furthermore, the immune subtypes identified with corresponding genes’ expression in PDAC tumor samples in TCGA showed an opposite correlation with OS to that of immune subtypes based on blood soluble ICK-related proteins (log-rank p =0.02). The immune-high subtype tumors displayed higher cytolytic activity (CYT) score than immune-low subtype tumors (p < 2E-16). Conclusion Five soluble ICK-related proteins were identified to be significantly associated with the risk and prognosis of PDAC. Patients who were classified as soluble immune-low subtype based on these biomarkers had better overall survival than those of the soluble immune-high subtype.

[1]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[2]  N. Navin,et al.  Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer , 2022, Nature Cancer.

[3]  Yong-Beom Park,et al.  Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis , 2022, Scientific reports.

[4]  Xiao-dong Wang,et al.  Tumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2 , 2022, Cells.

[5]  Ludmila V. Danilova,et al.  Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy , 2022, Cancer cell.

[6]  A. Tamori,et al.  Soluble immune checkpoint protein CD27 is a novel prognostic biomarker of HCC development in HCV-SVR patients. , 2022, The American journal of pathology.

[7]  C. del Fresno,et al.  Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer , 2022, Biomedicines.

[8]  G. Tortora,et al.  Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study , 2022, Human vaccines & immunotherapeutics.

[9]  Xiaoxin Tao,et al.  A comprehensive profiling of soluble immune checkpoints from the sera of patients with non‐small cell lung cancer , 2022, Journal of clinical laboratory analysis.

[10]  L. Strigari,et al.  The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study , 2021, Journal of personalized medicine.

[11]  Jiaqian Wang,et al.  Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers , 2021, Frontiers in Immunology.

[12]  H. Xiong,et al.  Roles of BTLA in Immunity and Immune Disorders , 2021, Frontiers in Immunology.

[13]  J. Weitz,et al.  LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer , 2021, Cancers.

[14]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[15]  A. Enk,et al.  Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients , 2021, Oncoimmunology.

[16]  May Tun Saung,et al.  CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. , 2020, Cancer letters.

[17]  Guixiang Liao,et al.  Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy , 2020, Frontiers in Immunology.

[18]  R. Andersson,et al.  The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data , 2020, Scientific Reports.

[19]  Xifeng Wu,et al.  Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study , 2020, Cancer Immunology, Immunotherapy.

[20]  Ying Cheng,et al.  Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival , 2020, Cancer science.

[21]  M. O'Hara,et al.  Challenges and Opportunities for Pancreatic Cancer Immunotherapy. , 2020, Cancer cell.

[22]  T. Putoczki,et al.  Emerging roles for the IL-6 family of cytokines in pancreatic cancer , 2020, Clinical science.

[23]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[24]  J. Valle,et al.  Pancreatic cancer , 2020, The Lancet.

[25]  S. Leung,et al.  Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types , 2020, Modern Pathology.

[26]  J. Debnath,et al.  Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I , 2020, Nature.

[27]  Xifeng Wu,et al.  Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients , 2019, Journal of Immunotherapy for Cancer.

[28]  D. M. Richards,et al.  HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality , 2019, Journal of Immunotherapy for Cancer.

[29]  J. Wolchok,et al.  Rational design of anti-GITR-based combination immunotherapy , 2019, Nature Medicine.

[30]  E. Collisson,et al.  Molecular subtypes of pancreatic cancer , 2019, Nature Reviews Gastroenterology & Hepatology.

[31]  D. Olive,et al.  Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma , 2019, Oncoimmunology.

[32]  Na Li,et al.  Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood. , 2018, Cancer biomarkers : section A of Disease markers.

[33]  Xiang Xu,et al.  Soluble immune checkpoints in cancer: production, function and biological significance , 2018, Journal of Immunotherapy for Cancer.

[34]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[35]  A. Wiestner,et al.  Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia , 2017, Haematologica.

[36]  V. Heinemann,et al.  Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer , 2017, Oncoimmunology.

[37]  S. Turan,et al.  Association of CTLA4 and CD28 Gene Variants and Circulating Levels of Their Proteins in Patients with Breast Cancer. , 2016, In vivo.

[38]  Jonathan H. Esensten,et al.  CD28 Costimulation: From Mechanism to Therapy. , 2016, Immunity.

[39]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[40]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[41]  I. Melero,et al.  Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism , 2014, Journal of Immunotherapy for Cancer.

[42]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[43]  H. Tao,et al.  Enhancement of soluble CD28 levels in the serum of Graves’ disease , 2014, Central-European journal of immunology.

[44]  David E. Adams,et al.  Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice. , 2013, Journal of autoimmunity.

[45]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[46]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[47]  C. Galbán,et al.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.

[48]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[49]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[50]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[51]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[52]  V. Shively,et al.  The soluble forms of CD28, CD86 and CTLA‐4 constitute possible immunological markers in patients with abdominal aortic aneurysm , 2007, Journal of internal medicine.

[53]  R. Straub,et al.  Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia , 2005, Leukemia.

[54]  D. Vignali,et al.  Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)1 , 2004, The Journal of Immunology.

[55]  M. Croft.  Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? , 2003, Nature Reviews Immunology.

[56]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[57]  T. Nguyen,et al.  Identification of three alternatively spliced variants of human CD28 mRNA. , 1999, Biochemical and biophysical research communications.

[58]  F. Hofstädter,et al.  A soluble form of CD137 (ILA/4‐1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis , 1998, European journal of immunology.

[59]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .